Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Atavistik Bio and Pfizer Collaborate to Discover Novel Allosteric Therapeutics
Jan 03, 2025
Contract Type
partnership
CambridgeBiotechnologySoftwareHealth CareScience And Engineering
Description
Atavistik Bio has partnered with Pfizer to utilize its AMPS platform in the discovery of novel precision allosteric therapeutics. The companies will work together to advance therapeutic innovations for patients in need, leveraging the potential of allostery to target disease-causing proteins and deliver more effective therapies.
Quick answer
Atavistik Bio and Pfizer Collaborate to Discover Novel Allosteric Therapeutics (January 3, 2025). Atavistik Bio is based in Cambridge, Massachusetts, United States.
What agreement did Atavistik Bio announce on January 3, 2025?
Atavistik Bio has partnered with Pfizer to utilize its AMPS platform in the discovery of novel precision allosteric therapeutics. The companies will work together to advance therapeutic innovations for patients in need, leveraging the potential of allostery to target disease-causing proteins and deliver more effective therapies.
What does Atavistik Bio do?
Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology.
Where is Atavistik Bio based?
Atavistik Bio is based in Cambridge, Massachusetts, United States.
Source: Fundz verified event record.
Company Information
Company
Atavistik Bio
Location
Cambridge, Massachusetts, United States
About
Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology. Since its inception, Atavistik Bio has rapidly established an emerging pipeline of allosteric therapeutics with the potential to achieve superior efficacy and tolerability profiles by leveraging the power of allostery. ATV-1601, a selective allosteric inhibitor for solid tumors, is anticipated to enter the clinic in early 2025. Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, Nextech Invest, and Lux Capital.